ArticleBMC infectious diseases2011
Unnecessary use of fluoroquinolone antibiotics in hospitalized patients.
Article in BMC infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- A Systematic Review of Antimicrobial Stewardship Interventions to Improve Management of Bacteriuria in Hospitalized Adults.The Annals of pharmacotherapy · 2023Pooled it
- Economic Burden of Inappropriate Antibiotic Prescribing Attributable to Dengue in Singapore.PharmacoEconomics - open · 2026Article
- Diagnosis of urinary tract infection in the emergency department - a real infection or an alarming indication for comprehensive geriatric assessment? A retrospective follow-up study.The Journal of frailty & aging · 2026Article
- Early discontinuation of antibiotic therapy initiated in the emergency department in older patients: a retrospective study.BMC geriatrics · 2026Observational
- Beyond Mimicking Enzymes: NewTAML/Peroxide Abstracts spJournal of the American Chemical Society · 2026Article
- Risk factors for Clostridioides difficile infection caused by ribotype 027 strains in the Veterans Affairs Healthcare System: a matched case-control study.Antimicrobial resistance and infection control · 2025Article
- Antimicrobial Stewardship Impact on Antibiotic Use in Three Tertiary Hospitals in Zambia: A Comparative Point Prevalence Survey.Antibiotics (Basel, Switzerland) · 2025Article
- Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens.Frontiers in microbiology · 2025Review
- Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study.Drug, healthcare and patient safety · 2025Article
- Fluoroquinolones and Biofilm: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Development of Patient Safety Measures to Identify Inappropriate Diagnosis of Common Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Antimicrobial resistance profiles ofJAC-antimicrobial resistance · 2024Article
- Management of Asymptomatic Bacteriuria and Urinary Tract Infections in Patients With Neurogenic Bladder and Factors Associated With Inappropriate Diagnosis and Treatment.Archives of physical medicine and rehabilitation · 2024Article
- Drugging evolution of antibiotic resistance at a regulatory network hub.Science advances · 2023Article
- ppGpp and RNA-polymerase backtracking guide antibiotic-induced mutable gambler cells.Molecular cell · 2023Article
- The Relationship between Ciprofloxacin Resistance and Genotypic Changes inPathogens (Basel, Switzerland) · 2022Article
- A Nonrestrictive Approach to Fluoroquinolone Stewardship at Two Community Hospitals.Open forum infectious diseases · 2022Article
- Impact of cascade reporting of antimicrobial susceptibility on fluoroquinolone and meropenem consumption at a Veterans' Affairs medical center.Infection control and hospital epidemiology · 2022Article
- Antibiotic Use and Presumptive Pathogens in the Veterans Affairs Healthcare System.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Observational
- Association between Consumption of Fluoroquinolones and Carbapenems and Their Resistance Rates inInterdisciplinary perspectives on infectious diseases · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundFluoroquinolones are among the most commonly prescribed antimicrobials and are an important risk factor for colonization and infection with fluoroquinolone-resistant gram-negative bacilli and for Clostridium difficile infection (CDI). In this study, our aim was to determine current patterns of inappropriate fluoroquinolone prescribing among hospitalized patients, and to test the hypothesis that longer than necessary treatment durations account for a significant proportion of unnecessary fluoroquinolone use.
methodsWe conducted a 6-week prospective, observational study to determine the frequency of, reasons for, and adverse effects associated with unnecessary fluoroquinolone use in a tertiary-care academic medical center. For randomly-selected adult inpatients receiving fluoroquinolones, therapy was determined to be necessary or unnecessary based on published guidelines or standard principles of infectious diseases. Adverse effects were determined based on chart review 6 weeks after completion of therapy.
resultsOf 1,773 days of fluoroquinolone therapy, 690 (39%) were deemed unnecessary. The most common reasons for unnecessary therapy included administration of antimicrobials for non-infectious or non-bacterial syndromes (292 days-of-therapy) and administration of antimicrobials for longer than necessary durations (234 days-of-therapy). The most common syndrome associated with unnecessary therapy was urinary tract infection or asymptomatic bacteriuria (30% of all unnecessary days-of-therapy). Twenty-seven percent (60/227) of regimens were associated with adverse effects possibly attributable to therapy, including gastrointestinal adverse effects (14% of regimens), colonization by resistant pathogens (8% of regimens), and CDI (4% of regimens).
conclusionsIn our institution, 39% of all days of fluoroquinolone therapy were unnecessary. Interventions that focus on improving adherence with current guidelines for duration of antimicrobial therapy and for management of urinary syndromes could significantly reduce overuse of fluoroquinolones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.